Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Individuals with high PLMs had significantly higher Fazekas and ARWMC total scores than those with a lower PLM index.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The study, published in the Journal of Clinical Investigation, shows that the ...